echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 12 Class 1 new drugs have been approved for clinical use!

    12 Class 1 new drugs have been approved for clinical use!

    • Last Update: 2022-02-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to the data on the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, since 2022, 118 clinical trial applications have passed the "implicit license"
    .


    Added 12 new category 1 drugs (excluding supplementary applications)


    118 12 class 1 new drugs JAK1 inhibitors, JAK2 inhibitors, KARS G12C inhibitors, SHP2 inhibitors, multi-targeted kinase inhibitors, Claudin 18.


    1.


    Mechanism of action: JAK1 inhibitor

    Indications: atopic dermatitis

    Indications: atopic dermatitis

    The FZJ-003 capsule declared by Fudan Zhangjiang has obtained an implied license for clinical trials, and the indication is atopic dermatitis
    .


    According to public information, FZJ-003 is an oral selective inhibitor of JAK1 and is currently conducting a phase 1 clinical trial for rheumatoid arthritis in China


    Oral selective inhibitor of JAK1, currently in phase 1 clinical trial for rheumatoid arthritis in China

    The JAK kinase family has become an important target for the treatment of various blood diseases and autoimmune diseases, among which JAK1 inhibitors have been proved in clinical studies to control the disease by regulating a variety of cytokines related to atopic dermatitis pathology
    .


    According to an earlier announcement by Fudan Zhangjiang, FZJ-003 was approved for a Phase 2 clinical trial for the treatment of moderate to severe atopic dermatitis


    Phase 2 clinical trial in the treatment of moderate to severe atopic dermatitis


    2.


    Mechanism of action: JAK2 inhibitor

    Indications: Systemic lupus erythematosus

    Indications: Systemic lupus erythematosus

    The OB756 tablet declared by Bangshun Pharmaceutical has obtained an implied license for a clinical trial, and the indication is systemic lupus erythematosus
    .


    According to an earlier press release from Bangshun Pharmaceuticals, OB756 is an oral selective JAK2 inhibitor independently developed by the company, which can exert therapeutic effects by targeting the kinase activity of JAK2 V617F and blocking the JAK/STAT signaling pathway


    By targeting the kinase activity of JAK2 V617F and blocking the JAK/STAT signaling pathway, it can play a therapeutic role in myelofibrosis

    3.
    Jiakesi Pharmaceutical: JAB-21822 tablets, JAB-3312 capsules

    3.
    Jiakesi Pharmaceutical: JAB-21822 tablets, JAB-3312 capsules

    Mechanism of action: KARS G12C inhibitor, SHP2 inhibitor

    Mechanism of action: KARS G12C inhibitor, SHP2 inhibitor

    Indications: Advanced solid tumors

    Indications: Advanced solid tumors

    JAB-21822 Tablets and JAB-3312 Capsules combination therapy received an implied approval from a clinical trial for the combination of the two in KRAS G12C-mutated advanced solid tumors
    .


    JAB-21822 is a potent and irreversible KRAS G12C inhibitor, which is currently undergoing phase 1 clinical trials of monotherapy in China and the United States; JAB-3312 is a SHP2 target It is a small-molecule inhibitor with high selectivity for SHP2.


    Combination of the two for KRAS G12C-mutated advanced solid tumors JAB-21822 JAB-3312

    Public information shows that after KRAS G12C inhibitor treatment develops resistance, the combination of SHP2 inhibitor is expected to effectively overcome and reverse the resistance problem of KRAS inhibitor, and the synergistic anti-cancer effect of the combination therapy has been proved in many clinical trials.

    .

    4.
    Taili Bio: TSN084 tablets

    4.
    Taili Bio: TSN084 tablets

    Mechanism of action: multi-targeted kinase inhibitor

    Mechanism of action: multi-targeted kinase inhibitor

    Indications: Advanced or metastatic malignant tumors

    Indications: Advanced or metastatic malignant tumors

    The TSN084 tablet filed by Teled Bio has obtained an implied license for a clinical trial for the indication of advanced or metastatic malignancies
    .


    Tyleris focuses on exploring the development of innovative therapies for drug-resistant tumors.


    Potential "first-in-class" novel multi-kinase inhibitors that act by targeting CDK8/19 and several other kinases closely related to tumorigenesis and immune escape

    Taili Bio said that TSN084 tablet is the company's first Sino-US dual reporting project, and it has obtained the US FDA's clinical trial license in October 2021
    .
    The company expects to conduct simultaneous dose escalation studies of the product in China and the United States
    .

    The company expects to conduct a simultaneous dose escalation study of the product in China and the United States

    5.
    Doer Bio: DR30303 for injection

    5.
    Doer Bio: DR30303 for injection

    Mechanism of action: monoclonal antibody targeting Claudin 18.
    2

    Mechanism of action: monoclonal antibody targeting Claudin 18.
    2

    Indication: Claudin 18.
    2 positive advanced solid tumor

    Indications: Claudin 18.
    2 positive advanced solid tumor Claudin 18.
    2 positive

    DR30303 for injection declared by Doer Bio, a subsidiary of Huadong Medicine, was approved for clinical use in China and is indicated for advanced solid tumors positive for Claudin 18.
    2
    .
    Claudin18.
    2 is highly expressed in many gastric cancer, pancreatic cancer, ductal adenocarcinoma, colorectal adenocarcinoma and other tumors, and is not expressed in other normal tissues other than differentiated gastric mucosal epithelial cells.
    ideal target for the development of immunotherapy for solid tumors
    .

    Claudin 18.
    2-positive advanced solid tumors

    According to the recent announcement of Huadong Medicine, DR30303 is a humanized monoclonal antibody targeting Claudin18.
    2 under development.
    Action (ADCC) and complement-dependent cytotoxicity (CDC) induce tumor cell death
    .
    This time, the product has been approved for a Phase 1 clinical trial, which will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DR30303 in the treatment of advanced solid tumors
    .

    The product was approved for a Phase 1 clinical trial,

    6.
    Pumis Bio: PM8002 Injection

    6.
    Pumis Bio: PM8002 Injection

    Mechanism of action: PD-L1/VEGF dual-target biological drug

    Mechanism of action: PD-L1/VEGF dual-target biological drug

    Indication: triple negative breast cancer

    Indication: triple negative breast cancer

    The class 1 biological new drug PM8002 injection declared by Pumis Bio has obtained an implied license for a clinical trial, and the indication is triple-negative breast cancer
    .
    According to the official website of Pumis Bio, PM8002 is a biological drug targeting PD-L1/VEGF
    .
    Previously, the product has been granted an implied license for clinical trials in China and is conducting a Phase 1/2a clinical trial for advanced solid tumors
    .

    Biopharmaceuticals targeting PD-L1/VEGF

    Blockade of vascular endothelial growth factor (VEGF) can not only inhibit the proliferation of vascular endothelial cells and angiogenesis, but also improve the tumor microenvironment and increase the infiltration of cytotoxic T lymphocytes in the tumor microenvironment
    .
    Blocking the VEGF and PD-L1 pathways at the same time can form a synergistic anticancer effect
    .
    According to public information, there are currently a number of dual-antibody or dual-specific fusion protein products targeting PD-1/VEGF or PD-L1/VEGF in the world that have entered the clinical research stage
    .

    Blocking the VEGF and PD-L1 pathways at the same time can form a synergistic anticancer effect
    .

    7.
    Pfizer: elranatamab

    7.
    Pfizer: elranatamab

    Mechanism of action: BCMA/CD3 double antibody

    Mechanism of action: BCMA/CD3 double antibody

    Indication: multiple myeloma

    Indication: multiple myeloma

    Pfizer's elranatamab received an implied license for a clinical trial, intended for the following indications: single agent or in combination with daratumumab, for at least 1 line of anti-multiple myeloma therapy (including lenadulum) amines and proteasome inhibitors) in patients with multiple myeloma
    .
    According to public information, the product is a bispecific antibody drug targeting BCMA and CD3, which has entered the phase 3 clinical research stage globally
    .
    In addition, the product was granted Fast Track designation by the FDA for the treatment of relapsed/refractory multiple myeloma
    .

    8.
    GlaxoSmithKline (GSK): gepotidacin tablets

    8.
    GlaxoSmithKline (GSK): gepotidacin tablets

    Mechanism of action: Triazaacenaphthene class II topoisomerase inhibitor

    Mechanism of action: Triazaacenaphthene class II topoisomerase inhibitor

    Indications: Simple urinary tract infection

    Indications: Simple urinary tract infection

    GlaxoSmithKline's gepotidacin tablet has been granted an implied license for a clinical trial for the treatment of uncomplicated urinary tract infection (acute cystitis) in adults and adolescents over 12 years of age
    .
    According to public information, the product is a potential "first-in-class" antibiotic with a new mechanism of action.
    It is a triazaacenaphthylene type II topoisomerase inhibitor and is in phase 3 clinical research worldwide
    .

    Uncomplicated urinary tract infection (acute cystitis) in adults and adolescents over 12 years of age

    Gepotidacin has a dual mechanism that selectively binds and inhibits DNA gyrase and DNA topoisomerase IV (type II topoisomerase), thereby inducing single-strand breaks in DNA during replication, thereby killing the purpose of pathogens
    .
    Early studies have shown that it is active against most strains of Escherichia coli and Staphylococcus saprophytes, including those resistant to existing antibiotics
    .
    Uncomplicated urinary tract infections are mainly caused by Escherichia coli and Staphylococcus saprophyticus infections.
    Patients have resistance to first-line drugs, and new antibiotics need to be developed to combat the increasingly widespread drug-resistant infections
    .

    It can selectively bind and inhibit DNA gyrase and DNA topoisomerase IV (type II topoisomerase) at the same time, thereby inducing single-strand breaks in DNA during the replication process, thereby achieving the purpose of killing pathogens

    9.
    Nektar Therapeutics: bempegaldesleukin for injection

    9.
    Nektar Therapeutics: bempegaldesleukin for injection

    Mechanism of action: agonists targeting the IL-2 signaling pathway

    Mechanism of action: agonists targeting the IL-2 signaling pathway

    Indication: head and neck squamous cell carcinoma

    Indication: head and neck squamous cell carcinoma

    The bempegaldesleukin for injection (development code name NKTR-214) filed by Nektar Therapeutics has obtained an implied license for clinical trials, and the indication is squamous cell carcinoma of the head and neck
    .
    According to public information, this is an agonist targeting the IL-2 signaling pathway, which has been granted a breakthrough therapy designation by the FDA
    .

    This is an agonist that targets the IL-2 signaling pathway and has been granted breakthrough therapy designation by the FDA

    As a cytokine, IL-2 has the ability to activate CD8 positive T cells, natural killer cells and promote their proliferation
    .
    A current R&D focus in the IL-2 field is the development of activators that selectively activate the IL-2 receptor signaling pathway in CD8-positive T cells
    .
    NKTR-214 is such an agonist, which is expected to stimulate the proliferation of CD8+ effector T cells, natural killer cells and CD4+ helper T cells by selectively activating the IL-2 signaling pathway
    .
    Globally, NKTR-214 has entered Phase 2/3 or registration clinical trials, and is being used in combination with various immune checkpoint inhibitors, including Opdivo, to explore the therapeutic effect on various cancers
    .

    It can selectively activate the IL-2 receptor signaling pathway in CD8-positive T cells.
    It is expected to stimulate the proliferation of CD8+ effector T cells, natural killer cells and CD4+ helper T cells by selectively activating the IL-2 signaling pathway
    .

    10.
    Junjing Bio: WJ01075 tablets

    10.
    Junjing Bio: WJ01075 tablets

    Indication: advanced malignant tumor

    Indication: advanced malignant tumor

    The WJ01075 tablet declared by Junjing Bio has been approved for clinical use in China, and the indication is advanced malignant tumor
    .
    According to public information, Junjing Biology was jointly invested and established by Junshi Biology and Weijing Biology
    .

    11.
    Shenghe Bio: IAE0972 for injection

    11.
    Shenghe Bio: IAE0972 for injection

    Indications: Advanced malignant solid tumors

    Indications: Advanced malignant solid tumors

    The IAE0972 for injection declared by Shenghe Bio has obtained an implied license for a clinical trial, and the indication is advanced malignant solid tumors
    .
    According to information on CDE's official website, this product is the first to obtain an implied license for clinical trials in China
    .

    It is hoped that the follow-up research of these class 1 new drugs under development will proceed smoothly and benefit patients as soon as possible
    .

    References:

    [1] China National Medical Products Administration Center for Drug Evaluation (CDE).
    Retrieved Jan 14, 2022, From https:// [2] Official websites and public information of each company

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.